乌司奴单抗治疗克罗恩病的临床研究进展

doi:10.12114/j.issn.1007-9572.2022.0504

摘要/Abstract

摘要： 近年来，随着对炎症性肠病（IBD）的深入研究，各种生物制剂不断涌现，IBD治疗进入新时代。乌司奴单抗是一种抗白介素（IL）-12/23的新型生物制剂，为传统药物治疗或抗肿瘤坏死因子α（TNF-α）治疗失败的克罗恩病（CD）患者提供了新选择。本文就乌司奴单抗治疗CD的作用机制、临床疗效、安全性、失应答及治疗调整做一综述，发现乌司奴单抗具有起效快、疗效显著和安全性高的优势，但目前其仍存在着临床应用时间短、临床经验不足等问题。未来需要更多临床研究及随访数据支持。

关键词: 克罗恩病, 乌司奴单抗, 组织学缓解, 安全性, 失应答, 强化治疗, 双生物制剂治疗, 综述

Abstract:

As the study of inflammatory bowel disease (IBD) advances, various biological agents for IBD are emerging, ushering in a new area of IBD treatment. Ustekinumab, an anti-interleukin-12/23 agent, is a new option for Crohn's disease patients with prior failure of traditional pharmacological treatment or tumor necrosis factor-alpha antagonist (TNF-α) . We reviewed the mechanisms of action, clinical effectiveness, safety, loss of response and the adjustment of therapy regarding ustekinumab in Crohn's disease, and summarized the strengths of ustekinumab treatment, such as rapid onset, significant efficacy and high safety. However, this treatment needs to be further examined by clinical and follow-up studies since it has been used for a short period of time with insufficient clinical evidence.

Key words: Crohn's disease, Ustekinumab, Histologic remission, Safety, Loss of response, Intensification treatment, Dual biologic therapy, Review

赵新,王英德. 乌司奴单抗治疗克罗恩病的临床研究进展[J]. 中国全科医学, 2022, 25(27): 3352-3357. DOI: 10.12114/j.issn.1007-9572.2022.0504.
Xin ZHAO,Yingde WANG. Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease[J]. Chinese General Practice, 2022, 25(27): 3352-3357. DOI: 10.12114/j.issn.1007-9572.2022.0504.

参考文献 50

[1]	TORRES J，MEHANDRU S，COLOMBEL J F，et al. Crohn's disease[J]. Lancet，2017，389（10080）：1741-1755. DOI：10.1016/S0140-6736(16)31711-1.
[2]	KAPLAN G G. The global burden of IBD：from 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol，2015，12（12）：720-727. DOI：10.1038/nrgastro.2015.150.
[3]	DASSOPOULOS T，SULTAN S，FALCK-YTTER Y T，et al. American Gastroenterological Association Institute technical review on the use of thiopurines，methotrexate，and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease[J]. Gastroenterology，2013，145（6）：1464-1478.e1-5. DOI：10.1053/j.gastro.2013.10.046.
[4]	LICHTENSTEIN G R，RUTGEERTS P，SANDBORN W J，et al. A pooled analysis of infections，malignancy，and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease[J]. Am J Gastroenterol，2012，107（7）：1051-1063. DOI：10.1038/ajg.2012.89.
[5]	LEE J W，CHOI C H，PARK J H，et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease[J]. Intest Res，2016，14（2）：146-151. DOI：10.5217/ir.2016.14.2.146.
[6]	MOLODECKY N A，SOON I S，RABI D M，et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time，based on systematic review[J]. Gastroenterology，2012，142（1）：46-54.e42；quize30. DOI：10.1053/j.gastro.2011.10.001.
[7]	LOVASZ B D，GOLOVICS P A，VEGH Z，et al. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe[J]. Dig Liver Dis，2013，45（4）：269-276. DOI：10.1016/j.dld.2012.08.020.
[8]	TURNER D，RICCIUTO A，LEWIS A，et al. STRIDE-Ⅱ：an update on the selecting therapeutic targets in inflammatory bowel disease（STRIDE）initiative of the international organization for the study of IBD（IOIBD）：determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology，2021，160（5）：1570-1583. DOI：10.1053/j.gastro.2020.12.031.
[9]	BILLIOUD V，SANDBORN W J，PEYRIN-BIROULET L. Loss of response and need for adalimumab dose intensification in Crohn's disease：a systematic review[J]. Am J Gastroenterol，2011，106（4）：674-684. DOI：10.1038/ajg.2011.60.
[10]	GISBERT J P，PANÉS J. Loss of response and requirement of infliximab dose intensification in Crohn's disease：a review[J]. Am J Gastroenterol，2009，104（3）：760-767. DOI：10.1038/ajg.2008.88.
[11]	宋阿倩，周秀彦.乌司奴单抗在治疗克罗恩病中的作用机制[J]. 胃肠病学和肝病学杂志，2021，30（8）：946-949.
[12]	MOSCHEN A R，TILG H，RAINE T. IL-12，IL-23 and IL-17 in IBD：immunobiology and therapeutic targeting[J]. Nat Rev Gastroenterol Hepatol，2019，16（3）：185-196. DOI：10.1038/s41575-018-0084-8.
[13]	NEURATH M F. IL-23 in inflammatory bowel diseases and colon cancer[J]. Cytokine Growth Factor Rev，2019，45：1-8. DOI：10.1016/j.cytogfr.2018.12.002.
[14]	DEEPAK P，SANDBORN W J. Ustekinumab and anti-interleukin-23 agents in Crohn's disease[J]. Gastroenterol Clin North Am，2017，46（3）：603-626. DOI：10.1016/j.gtc.2017.05.013.
[15]	FEAGAN B G，SANDBORN W J，GASINK C，et al. Ustekinumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med，2016，375（20）：1946-1960.
[16]	RUTGEERTS P，GASINK C，CHAN D，et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease[J]. Gastroenterology，2018，155（4）：1045-1058. DOI：10.1053/j.gastro.2018.06.035.
[17]	LI K，FRIEDMAN J R，CHAN D，et al. Effects of ustekinumab on histologic disease activity in patients with Crohn's disease[J]. Gastroenterology，2019，157（4）：1019-1031.e7. DOI：10.1053/j.gastro.2019.06.037.
[18]	SANDBORN W J，REBUCK R，WANG Y H，et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease：the IM-UNITI trial[J]. Clin Gastroenterol Hepatol，2022，20（3）：578-590.e4. DOI：10.1016/j.cgh.2021.02.025.
[19]	HANAUER S B，SANDBORN W J，FEAGAN B G，et al. IM-UNITI：three-year efficacy，safety，and immunogenicity of ustekinumab treatment of Crohn's disease[J]. J Crohns Colitis，2020，14（1）：23-32. DOI：10.1093/ecco-jcc/jjz110.
[20]	BIEMANS V B C，VAN DER MEULEN-DE JONG A E，VAN DER WOUDE C J，et al. Ustekinumab for Crohn's disease：results of the ICC registry，a nationwide prospective observational cohort study[J]. J Crohns Colitis，2020，14（1）：33-45. DOI：10.1093/ecco-jcc/jjz119.
[21]	GONCZI L，SZANTO K，FARKAS K，et al. Clinical efficacy，drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab-A prospective，multicenter cohort from Hungary[J]. Dig Liver Dis，2022，54（2）：207-213. DOI：10.1016/j.dld.2021.07.008.
[22]	ROGERIO P，JULIO C，LILIANA C，et al. P008 long-term effectiveness and safety of ustekinumab for the treatment of crohn's disease：a Brazilian multicentre real-world study[J]. Am J Gastroenterol，2020，115（Suppl 1）：S2. DOI：10.14309/01.ajg.0000722828.45880.db.
[23]	姚嘉茵，宋孝美，余乔，等.乌司奴单克隆抗体治疗难治性克罗恩病的短期疗效分析：一项多中心回顾性观察性研究[J]. 中华炎性肠病杂志，2021，5（2）：151-155. DOI：10.3760/cma.j.cn101480-20210326-00025.
[24]	HARRIS K A，HORST S，GADANI A，et al. Patients with refractory Crohn's disease successfully treated with ustekinumab[J]. Inflamm Bowel Dis，2016，22（2）：397-401. DOI：10.1097/MIB.0000000000000624.
[25]	STRAATMIJER T，BIEMANS V B C，HOENTJEN F，et al. Ustekinuma b for Crohn's disease：two-year results of the initiative on crohn and colitis（ICC） registry，a nationwide prospective observational cohort study[J]. J Crohns Colitis，2021，15（11）：1920-1930. DOI：10.1093/ecco-jcc/jjab081.
[26]	BAR-GIL SHITRIT A，BEN-YA ACOV A，SITERMAN M，et al. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease：a multicenter Israeli study[J]. United European Gastroenterol J，2020，8（4）：418-424. DOI：10.1177/2050640620902956.
[27]	BIEMANS V B C，VAN DER WOUDE C J，DIJKSTRA G，et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment[J]. Aliment Pharmacol Ther，2020，52（1）：123-134. DOI：10.1111/apt.15745.
[28]	BUISSON A，NANCEY S，MANLAY L，et al. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease[J]. United European Gastroenterol J，2021，9（5）：552-560. DOI：10.1002/ueg2.12068.
[29]	PAPAMICHAEL K，GILS A，RUTGEERTS P，et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD：evolution in the definition and management of primary nonresponse[J]. Inflamm Bowel Dis，2015，21（1）：182-197. DOI：10.1097/MIB.0000000000000202.
[30]	WONG U，CROSS R K. Primary and secondary nonresponse to infliximab：mechanisms and countermeasures[J]. Expert Opin Drug Metab Toxicol，2017，13（10）：1039-1046. DOI：10.1080/17425255.2017.1377180.
[31]	YANG H S，LI B Y，GUO Q，et al. Systematic review with meta-analysis：loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases[J]. Aliment Pharmacol Ther，2022，55（7）：764-777. DOI：10.1111/apt.16802.
[32]	LIEFFERINCKX C，VERSTOCKT B，GILS A，et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies：a national cohort study[J]. J Crohns Colitis，2019，13（11）：1401-1409. DOI：10.1093/ecco-jcc/jjz080.
[33]	BEN-HORIN S，CHOWERS Y. Tailoring anti-TNF therapy in IBD：drug levels and disease activity[J]. Nat Rev Gastroenterol Hepatol，2014，11（4）：243-255. DOI：10.1038/nrgastro.2013.253.
[34]	UNGAR B，LEVY I，YAVNE Y，et al. Optimizing anti-TNF-α therapy：serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases[J]. Clin Gastroenterol Hepatol，2016，14（4）：550-557.e2. DOI：10.1016/j.cgh.2015.10.025.
[35]	UNGAR B，CHOWERS Y，YAVZORI M，et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab[J]. Gut，2014，63（8）：1258-1264. DOI：10.1136/gutjnl-2013-305259.
[36]	YAO J Y，ZHANG M，WANG W，et al. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease：a Chinese real-world study[J]. BMC Gastroenterol，2021，21（1）：380. DOI：10.1186/s12876-021-01946-8.
[37]	HANZEL J，ZDOVC J，KURENT T，et al. Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn's disease likely to achieve endoscopic and biochemical remission[J]. Clin Gastroenterol Hepatol，2021，19（1）：111-118.e10. DOI：10.1016/j.cgh.2020.02.033.
[38]	ADEDOKUN O J，XU Z H，GASINK C，et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease[J]. Gastroenterology，2018，154（6）：1660-1671. DOI：10.1053/j.gastro.2018.01.043.
[39]	SPARROW M P，PAPAMICHAEL K，WARD M G，et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response[J]. J Crohns Colitis，2020，14（4）：542-556. DOI：10.1093/ecco-jcc/jjz162.
[40]	COLOMBEL J F，SANDBORN W J，REINISCH W，et al. Infliximab，azathioprine，or combination therapy for Crohn's disease[J]. N Engl J Med，2010，362（15）：1383-1395. DOI：10.1056/NEJMoa0904492.
[41]	PANACCIONE R，GHOSH S'MIDDLETON S，et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology，2014，146（2）：392-400.e3. DOI：10.1053/j.gastro.2013.10.052.
[42]	YZET C，DIOUF M，SINGH S，et al. No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases：a meta-analysis[J]. Clin Gastroenterol Hepatol，2021，19（4）：668-679.e8. DOI：10.1016/j.cgh.2020.06.071.
[43]	FUMERY M，PEYRIN-BIROULET L，NANCEY S，et al. Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks in Crohn's disease：a multicenter study[J]. J Crohns Colitis，2020：2020Sep8；jjaa177. DOI：10.1093/ecco-jcc/jjaa177.
[44]	SEDANO R，GUIZZETTI L，MCDONALD C，et al. Intravenous ustekinumab reinduction is effective in prior biologic failure Crohn's disease patients already on every-4-week dosing[J]. Clin Gastroenterol Hepatol，2021，19（7）：1497-1498.e1. DOI：10.1016/j.cgh.2020.07.064.
[45]	DALAL R S，NJIE C，MARCUS J，et al. Predictors of ustekinumab failure in Crohn's disease after dose intensification[J]. Inflamm Bowel Dis，2021，27（8）：1294-1301. DOI：10.1093/ibd/izaa282.
[46]	AHMED W，GALATI J，KUMAR A，et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease：a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol，2022，20（3）：e361-379. DOI：10.1016/j.cgh.2021.03.034.
[47]	YANG E，PANACCIONE N，WHITMIRE N，et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease[J]. Aliment Pharmacol Ther，2020，51（11）：1031-1038. DOI：10.1111/apt.15719.
[48]	BATTAT R，KOPYLOV U，SZILAGYI A，et al. Vitamin B₁₂ deficiency in inflammatory bowel disease：prevalence，risk factors，evaluation，and management[J]. Inflamm Bowel Dis，2014，20（6）：1120-1128. DOI：10.1097/MIB.0000000000000024.
[49]	BATTAT R，DUIJVESTEIN M，VANDE CASTEELE N，et al. Serum concentrations of 7α-hydroxy-4-cholesten-3-one are associated with bile acid diarrhea in patients with Crohn's disease[J]. Clin Gastroenterol Hepatol，2019，17（13）：2722-2730.e4. DOI：10.1016/j.cgh.2018.11.012.
[50]	LICHTENSTEIN G R，LOFTUS E V，ISAACS K L，et al. ACG clinical guideline：management of Crohn's disease in adults[J]. Am J Gastroenterol，2018，113（4）：481-517. DOI：10.1038/ajg.2018.27.